U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417397) titled 'Adjuvant TACE in HCC With High-risk Recurrence Factors' on Feb. 11.
Brief Summary: The 5-year recurrence rate after curative hepatectomy of hepatocellular carcinoma (HCC) remains as high as 70%. According to the Chinese Liver Cancer Staging (CNLC), transarterial chemoembolization (TACE) is strongly recommended as an adjuvant therapy after curative hepatectomy, aiming to reduce postoperative recurrence and ultimately improve overall survival. However, the effectiveness of such adjuvant postoperative therapy remains controversial. In contrast, guidelines from other countries or regions do not recommend adjuvant TACE after curative hep...